Terremoto Biosciences | $108,000,000 | (Apr 16, 2026)
Ralio | $2,500,000 | (Apr 16, 2026)
Parasail | $32,000,000 | (Apr 16, 2026)
Neumora
United States
- Watertown, MA
- 17/10/2022
- Series B
- $112,000,000
Brain diseases are not “one-size-fits-all” - but the industry currently treats them that way. We are focused on conquering one of the greatest medical challenges of our generation: the global brain disease crisis.
Our proprietary toolbox of state-of-the-art neural network technologies is built to integrate multiple types of data across genomics, imaging, electroencephalogram (EEG), digital and clinical domains to create Data Biopsy Signatures™ that map the underlying disease mechanisms to Precision Phenotypes™ that identify distinct patient subtypes. Through this approach, we have the ability to develop and match the right therapeutic to the right patient populations for more targeted treatments.
Together, we are committed to creating a new era in modern precision medicine. Brain disease doesn’t wait. And neither will we.
- Industry Biotechnology Research
- Website https://neumoratx.com/
- LinkedIn https://www.linkedin.com/company/neumora/
spektr | $20,000,000 | (Apr 16, 2026)
Modern Relay | $3,000,000 | (Apr 16, 2026)
Paxos Labs | $12,000,000 | (Apr 16, 2026)
Gitar | $9,000,000 | (Apr 16, 2026)
STORM Therapeutics Limited | $56,000,000 | (Apr 16, 2026)
Traza | $2,100,000 | (Apr 16, 2026)
Smartwage Società Benefit | $2,000,000 | (Apr 15, 2026)
Synera | $40,000,000 | (Apr 15, 2026)
Turion Space | $75,000,000 | (Apr 15, 2026)